Semaglutide MIMS information: what prescribers and patients need to know

You've found a MIMS entry for semaglutide, here's how to read it in context

MIMS (the Monthly Index of Medical Specialities) is a prescriber-facing reference compiled from manufacturers' Summaries of Product Characteristics (SmPCs). When a GP or pharmacist looks up semaglutide, they typically see entries for both Wegovy and Ozempic. The critical distinction is right there in the licensed indication: Ozempic carries a type 2 diabetes licence; Wegovy carries a weight-management licence. MHRA licensing governs which indication is permitted in UK clinical practice, and prescribing outside a medicine's licence requires explicit clinical justification. So if weight loss is the goal, Wegovy is the relevant entry.

The NHS medicines page for semaglutide summarises the patient-facing version of this same information and is a reliable place to check the basics in plain English. For the full prescribing detail (contraindications, drug interactions, storage conditions, the complete side-effect profile) the SmPC on the electronic Medicines Compendium (eMC) is the authoritative source, and it's what MIMS itself draws from.

One practical habit worth building: before acting on any secondary source, cross-check the eMC entry directly. It takes under a minute to search by brand name at medicines.org.uk and pull up the current approved labelling. Prescribing information moves, a MIMS edition can lag a post-approval update by a month or two, whereas the eMC reflects the current authorised text.

What the licensed prescribing schedule for Wegovy actually looks like

The standard escalation pathway starts with semaglutide at 0.25 mg weekly and increases roughly every four weeks (through 0.5 mg, 1.0 mg and 1.7 mg) reaching the 2.4 mg maintenance dose. The purpose of the slow ramp is tolerability: gastrointestinal side effects are most common at initiation and after dose increases, and a gradual escalation gives the body time to adjust. Prescribers can hold at any rung longer if needed. The highest approved weekly dose in the UK is now 7.2 mg, following MHRA approval of a dedicated single-dose pen in April 2026.

Clinical trial evidence for 2.4 mg comes primarily from the STEP 1 trial (68 weeks), which reported an average body-weight reduction of around 15% compared with placebo, in adults with obesity without diabetes alongside lifestyle support. The STEP 1 paper in the New England Journal of Medicine remains the reference that MIMS-level summaries draw on for efficacy figures. Results vary between individuals; a prescriber reviews whether the medicine is working well enough to continue.

For patients and clinicians curious about how semaglutide compares with tirzepatide (Mounjaro), you can read about the full Wegovy prescribing picture and the head-to-head SURMOUNT-5 data there. Dose selection and medicine choice are always clinical decisions.

NICE criteria and what they mean for private and NHS access

NICE's technology appraisal TA875 sets the conditions under which semaglutide (Wegovy) is recommended on the NHS: adults with a BMI of 35 or above and at least one weight-related comorbidity, used within a specialist weight management service with multidisciplinary support, for a maximum of two years. Lower BMI thresholds apply for people from certain ethnic backgrounds. NICE also advises reviewing continuation if less than 5% weight loss is achieved after six months at the maintenance dose.

NHS access through this route typically involves a specialist referral and a waiting list. Privately, the licensed eligibility criteria from the SmPC apply: BMI 30 or above, or 27 or above with a weight-related condition such as hypertension, high cholesterol, prediabetes or obstructive sleep apnoea. A prescriber still assesses the full picture, BMI alone does not determine suitability. If you're weighing up the cost of Wegovy treatment through a private route, that page covers what a legitimate private prescription includes and what price ranges actually reflect.

The NHS phased rollout for tirzepatide (under NICE TA1026) is expanding through 2026 and 2027 with different BMI and comorbidity thresholds; our weight-loss treatment overview covers both medicines side by side if you want to explore the options.

Side effects and safety considerations prescribers flag

The side-effect profile for semaglutide is well-characterised. Gastrointestinal effects dominate: nausea, vomiting, diarrhoea, constipation, reflux, burping and fatigue are the most commonly reported, particularly at the start of treatment or after a dose increase. Most people find these settle within a week or two. Injection-site reactions and headaches are also reported.

Serious events are infrequent but matter. The MHRA highlighted acute pancreatitis as a known risk in its January 2026 Drug Safety Update for GLP-1 medicines: severe, persistent stomach pain that may spread to the back, with or without vomiting, calls for urgent medical assessment rather than a wait-and-see approach. Gallbladder problems and, in people with diabetic retinopathy, sudden vision changes are also listed in the SmPC as requiring prompt review.

Semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and it is not licensed for under-18s. Women using oral contraceptives alongside tirzepatide (a distinct medicine, but the prescribing population often has questions about both) should note separate contraception advice; for semaglutide specifically, NHS guidance does not identify the same interaction risk with the pill as exists for tirzepatide, though any concerns are worth raising with your prescriber. Our clinical team is available seven days a week for aftercare questions, and if you want to understand how semaglutide 1 mg fits into the dose escalation journey, that page goes into the detail. You can also read about the semaglutide 2 mg stage, which covers what to expect as you approach the higher end of the schedule, and if you have questions about the top of the maintenance range, our semaglutide 3 mg guide explains what that phase involves. You can reach our clinical team here. You can also report any suspected side effects directly at the MHRA's Yellow Card scheme, which is open to patients and prescribers alike.

If you'd like to check whether you'd be suitable for treatment, start a free consultation with our prescribers, it's reviewed the same day by a GPhC-registered independent prescriber, not automated software.